Whanin Pharm (016580) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Whanin Pharm stock KRW 11,707, price KRW 10,740, upside +9.0%, quality 42 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 9,230 KRW – 20,958 KRW · fair‑value band 7,898 KRW – 16,478 KRW · the 10,740 KRW price screens below the 11,707 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Whanin Pharm in your weekly email
Every Wednesday you see whether Whanin Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea.
Show moreShow less
The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, antiseizure, antidepressant, antipsychotic, central nervous system stimulant, anti-dementia, nootropic, alcohol use disorder, anti-Parkinson, multivitamin, external preparation, medical device, and sedative, hypnotic, and autonomic nervous system medications.
The company was founded in 1978 and is headquartered in Seoul, South Korea.
Stock analysis
Whanin Pharm (016580) currently trades at 10,740 KRW, while our model-based Fair Value estimate is 11,707 KRW, so the stock looks roughly fairly valued today (gap 8.3%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 15,797 KRW per share, and 13 of the 26 models we run sit above the 10,740 KRW price.
Bear case: the Dividend Discount group reads lowest at 3,006 KRW, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 7,898 KRW (bear) to 16,478 KRW (bull), the price of 10,740 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Whanin Pharm reported revenue of 255B KRW in FY2025 versus 178B KRW in FY2021, a compound +9.5%/yr. Reported net income was 13.6B KRW in FY2025, compounding −15.5%/yr from FY2021.
Key figures
Market cap 175B KRW (≈ $129M) Micro · P/E ratio 9.8 · P/S ratio 0.64 · EPS (TTM) 1,106 KRW · Dividend yield 2.8% · Net margin 7.5% · Return on equity 5.1% · Return on assets (EBIT) 6.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (medium confidence).
What moves the price
The share trades about 10% below its 52-week high and 16% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 9%, 016580 screens cheaper than that median.
Fair Value models
Bear7,898 KRWFair Value 11,707 KRWBull16,478 KRW
Price 10,740 KRW · Upside +9.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (691.60 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic)
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’11
’12
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−8.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.4%
Dividend (yield on the price)2.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 5%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +24.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside+9.0% · Above median
Profitability
Return on equity (12 months)5.1% · Below median
Return on assets2.8% · Below median
Net margin (12 months)7.5% · Below median
Operating margin (12 months)11.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)11.4% · Above median
Dividend yield (12 months)2.8% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Whanin Pharm Fair Value". https://www.fairvalue-calculator.com/stock/016580
Frequently asked questions
Is Whanin Pharm (016580) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 11,707 KRW versus a price of 10,740 KRW, about +9% upside (fairly valued).
What is the fair value of 016580?
Our model-based fair value for Whanin Pharm is 11,707 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 10,740 KRW.
What is the quality score of 016580?
Whanin Pharm has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Whanin Pharm (016580)?
Our model-based price target is the fair value of 11,707 KRW (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 7,898 KRW, optimistic scenario 16,478 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Whanin Pharm stock forecast for 2026?
Our models put fair value at 11,707 KRW, about +9% upside versus a price of 10,740 KRW (fairly valued). Cautious scenario 7,898 KRW, optimistic scenario 16,478 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Whanin Pharm (016580)?
Whanin Pharm reported trailing-twelve-month revenue of about 273B KRW (latest available figure, as of Nov 8, 2026).
Does Whanin Pharm pay a dividend?
Whanin Pharm currently shows a dividend yield of 2.79% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Whanin Pharm (016580) and when is the ex-dividend date?
Whanin Pharm pays a dividend of 300.00 KRW per share a year, a dividend yield of 2.8%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 1997. The payout ratio is 27.1% of earnings. Free cash flow covers the dividend 0.52 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Whanin Pharm (016580)?
For today's price to be fair in a discounted-cash-flow model, Whanin Pharm would have to grow free cash flow by +27.3 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.3 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 016580 use?
Our models discount Whanin Pharm at 11.6 %: a base by market capitalisation (micro), damped by beta 0.17, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Whanin Pharm that is +27.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Whanin Pharm (016580) delivered so far?
Over the past 5 years revenue at Whanin Pharm grew +8.3 % a year. The price currently implies free-cash-flow growth of +27.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Whanin Pharm (016580) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Whanin Pharm (+27.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Whanin Pharm (016580)?
The free-cash-flow yield on the price is 1.64 %: that much free cash flow Whanin Pharm produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Whanin Pharm (016580)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Whanin Pharm it is 11,707 KRW per share (as of Nov 8, 2026), against a price of 10,740 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Whanin Pharm stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 016580 trades below its calculated fair value: price 10,740 KRW, fair value 11,707 KRW, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 016580?
No. The price is what the market pays today (10,740 KRW); the fair value is what the company's own numbers justify (11,707 KRW). For Whanin Pharm the two are 966.62 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Whanin Pharm worth?
The market values Whanin Pharm at about 175B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 10,740 KRW; our models calculate a fair value of 11,707 KRW per share.
What do the bullish and bearish scenarios say about 016580?
Our models span a range for Whanin Pharm: cautious scenario 7,898 KRW, base 11,707 KRW, optimistic 16,478 KRW per share (as of Nov 8, 2026, price 10,740 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 016580?
Whanin Pharm trades at a price-to-earnings ratio of 9.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 11,707 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2012 to 2025), reported earnings: 11.1. Other multiples: P/B 0.4, P/S 0.6, EV/EBITDA 3.5.
How solid is the balance sheet of Whanin Pharm (016580)?
Balance-sheet figures for Whanin Pharm (as of Nov 8, 2026): return on equity 5.1%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 016580 from its 52-week high?
Whanin Pharm trades at 10,740 KRW, about 10% below its 52-week high of 11,930 KRW and 16% above the low of 9,230 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 11,707 KRW is for.
Which stocks are comparable to Whanin Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Whanin Pharm stock attractive at the current price?
The data as of Nov 8, 2026: price 10,740 KRW, calculated fair value 11,707 KRW (+9%), Quality Score 42/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 016580 calculated?
We run Whanin Pharm through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 11,707 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Whanin Pharm currently trades 8% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Whanin Pharm (016580)?
The closing price on Nov 9, 2026 was 10,740 KRW. Our model-based fair value is 11,707 KRW, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Whanin Pharm right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (7,898 KRW to 16,478 KRW) leaves room in how you read the outcome.
Key figures of Whanin Pharm
How large is the market capitalisation of Whanin Pharm (016580)?
The market capitalisation of Whanin Pharm is 175B KRW (≈ $129M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Whanin Pharm (016580)?
The price-to-sales ratio of Whanin Pharm is 0.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Whanin Pharm (016580)?
Earnings per share at Whanin Pharm are 1,106 KRW (price ÷ EPS = P/E 9.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Whanin Pharm (016580)?
The dividend yield of Whanin Pharm is 2.8% (payout 27.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Whanin Pharm (016580)?
The net margin of Whanin Pharm is 7.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Whanin Pharm (016580)?
The return on equity (ROE) of Whanin Pharm is 5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Whanin Pharm (016580)?
On an EBIT basis the return on assets of Whanin Pharm is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Whanin Pharm (016580)?
The operating margin of Whanin Pharm is 11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Whanin Pharm (016580)?
Revenue at Whanin Pharm is growing +11.4% versus a year earlier (3y avg +8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Whanin Pharm (016580)?
Earnings per share at Whanin Pharm are growing +99.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Whanin Pharm in the live analysis
One click puts Whanin Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026